Plus Historical Financial Ratios
| PSTV Stock | USD 1.20 0.32 21.05% |
Plus Therapeutics is promptly reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Capex To Depreciation of 0.19, Ev To Sales of 0.25, Payables Turnover of 2.67 or Sales General And Administrative To Revenue of 1.49 will help investors to properly organize and evaluate Plus Therapeutics financial condition quickly.
Plus |
About Plus Financial Ratios Analysis
Plus TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Plus Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Plus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Plus Therapeutics history.
Plus Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Plus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Plus Therapeutics sales, a figure that is much harder to manipulate than other Plus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Plus Therapeutics dividend as a percentage of Plus Therapeutics stock price. Plus Therapeutics dividend yield is a measure of Plus Therapeutics stock productivity, which can be interpreted as interest rate earned on an Plus Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Net Debt To E B I T D A
A leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA).Most ratios from Plus Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics' Stock Based Compensation To Revenue is fairly stable compared to the past year. Payables Turnover is likely to climb to 2.67 in 2025, despite the fact that PTB Ratio is likely to grow to (4.45).
| 2024 | 2025 (projected) | Dividend Yield | 0.002524 | 0.002244 | Price To Sales Ratio | 1.29 | 1.22 |
Plus Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Plus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Plus Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 0.47 | 29.52 | 37.51 | 1.12 | 1.29 | 1.22 | |
| Ptb Ratio | 2.95 | 1.17 | 1.3 | (4.08) | (4.69) | (4.45) | |
| Free Cash Flow Yield | (1.0) | (0.82) | (1.6) | (2.37) | (0.14) | (0.15) | |
| Operating Cash Flow Per Share | (28.57) | (12.76) | (7.41) | (4.09) | (0.16) | (0.17) | |
| Capex To Depreciation | 1.35 | 0.36 | 0.82 | 0.25 | 0.2 | 0.19 | |
| Pb Ratio | 2.95 | 1.17 | 1.3 | (4.08) | (4.69) | (4.45) | |
| Ev To Sales | (0.34) | 25.06 | (18.18) | 0.23 | 0.26 | 0.25 | |
| Free Cash Flow Per Share | (30.24) | (12.93) | (7.7) | (4.14) | (0.16) | (0.17) | |
| Roic | (1.08) | (0.74) | (1.46) | (2.8) | (3.22) | (3.06) | |
| Inventory Turnover | 10.73 | 50.14 | (45.76) | (9.43) | (10.84) | (10.3) | |
| Net Income Per Share | (31.67) | (17.78) | (11.91) | (4.24) | (0.2) | (0.21) | |
| Days Of Inventory On Hand | 34.02 | 7.28 | (7.98) | (38.71) | (34.84) | (33.1) | |
| Payables Turnover | 16.41 | 3.42 | 0.0253 | 0.0851 | 1.83 | 2.67 | |
| Sales General And Administrative To Revenue | 0.69 | 21.14 | 45.71 | 1.74 | 1.57 | 1.49 | |
| Capex To Revenue | 0.009574 | 1.63 | 2.27 | 0.0326 | 0.0293 | 0.0278 | |
| Pocfratio | (1.06) | (1.23) | (0.65) | (0.43) | (7.24) | (7.6) | |
| Interest Coverage | (8.66) | (13.4) | (27.72) | (33.72) | (30.35) | (31.87) | |
| Capex To Operating Cash Flow | (0.0585) | (0.014) | (0.0392) | (0.0125) | (0.0138) | (0.0145) | |
| Pfcf Ratio | (1.0) | (1.22) | (0.62) | (0.42) | (7.14) | (7.49) | |
| Days Payables Outstanding | 106.66 | 14.4K | 4.3K | 179.22 | 161.3 | 169.37 | |
| Income Quality | 0.54 | 1.02 | 0.77 | 0.64 | 0.97 | 1.13 | |
| Roe | (3.08) | (1.32) | (3.23) | 9.88 | 8.89 | 9.34 | |
| Pe Ratio | (0.96) | (0.89) | (0.4) | (0.41) | (5.88) | (6.18) | |
| Return On Tangible Assets | (0.56) | (0.8) | (0.66) | (0.89) | (1.21) | (1.4) | |
| Earnings Yield | (3.84) | (1.05) | (1.13) | (2.48) | (2.42) | (0.18) | |
| Intangibles To Total Assets | 0.0378 | 0.0192 | 0.0195 | 0.0364 | 0.0418 | 0.0397 | |
| Net Debt To E B I T D A | 0.2 | 0.91 | 0.66 | 0.34 | 0.31 | 0.46 | |
| Current Ratio | 1.07 | 3.36 | 1.84 | 0.92 | 1.05 | 1.0 | |
| Debt To Equity | 2.31 | 0.65 | 0.88 | (3.1) | (2.79) | (2.65) | |
| Capex Per Share | 1.67 | 0.18 | 0.29 | 0.0509 | 0.002199 | 0.002089 | |
| Revenue Per Share | 75.85 | 1.03 | 0.13 | 1.56 | 1.8 | 1.71 | |
| Debt To Assets | 0.58 | 0.32 | 0.24 | 0.37 | 0.33 | 0.25 | |
| Enterprise Value Over E B I T D A | (1.12) | (0.1) | 0.22 | (0.0885) | (0.0797) | (0.0837) | |
| Book Value Per Share | 10.27 | 13.45 | 3.68 | (0.43) | (0.49) | (0.47) | |
| Cash Per Share | 28.27 | 22.83 | 10.35 | 2.72 | 3.13 | 2.98 | |
| Ev To Operating Cash Flow | (0.9) | (0.13) | 0.31 | (0.0874) | (0.0787) | (0.0826) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.